Eurofins Scientific posted a 29% year-on-year increase in earnings per share for the first half of 2026, alongside an adjusted EBITDA margin of 23.7% that exceeded its own objectives. Reported EBITDA margin reached 23.3%, a 190 basis point improvement, while free cash flow surged 46% to EUR 403 million, driving cash conversion to a record 47%. Organic growth came in at 2.7%, held back by a 2.9% foreign-exchange headwind and softness in biopharma, though the rest of the world delivered 9% organic revenue growth. The company also executed EUR 200 million in share buybacks, kept leverage stable at 2.2 times, and saw margin gains of 210 basis points in Europe and 230 basis points in North America excluding one-time items.
Eurofins Scientific SEReports 29% EPS growth, record cash conversion, and EUR 200 million in buybacks.